Kornimate/medical-research-clean huggingface dataset:
prospective study of colonoscopic resection of large polyps and flat lesions

Conditions: Colon Polyps

Summary: with this study, the investigators plan to review the performance of colonoscopic resection of large (\> 1 cm) and flat lesions in the colon. the findings will help us define the role of colonoscopic resection of colon polyps and flat lesions and identity areas for improvement. the data will be used for continuing quality improvement and presenting our outcomes at academic meetings and publishing our results in peer reviewed journals.

our goal is to collect data from our endoscopy reports (endoscopy clinic database) and electronic medical record system (clinic station) to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025. specific variable to be reviewed: 1. patient demographics: age, sex, race, height, weight, bmi (patient privacy will be acknowledged). 2. indications for colonoscopy (screening, surveillance, symptoms or tertiary referral \[emr\]) 3. comorbid conditions: cancer and surgical history, medical conditions. 4. colonoscopy procedure: quality of colon preparation (using the boston bowel preparation scale) 0 - 3 for each section of the colon (ascending, transverse, descending and total colon), cecal intubation rate, cecal intubation and total procedure time, type of colonoscope (if co2 was used in the procedure and techniques for colonoscope insertion, including position changes. 5. examination findings: number of polyps and nature of polyps removed (site, size, surface, vascular pattern); type of polyp removed (serrated and sessile (flat); optical features and histology of polyps. 6. resection techniques: biopsy, snare resection, endoscopic mucosal resection, endoscopic submucosal dissection etc. 7. including pathology report findings so that a comparison can be made of the optical features and actual pathology report. 8. outcomes of colonoscopy: complete or incomplete resection, local recurrence, need for surgery, etc 9. outcome of colonoscopy: complications (bleeding and perforation).

Eligibility criteria:
inclusion criteria: 1. all patients who have been referred for endoscopic resection of large polyps (\>1 cm) and flat lesions. exclusion criteria: n/a

Keywords: colon polyps large polyps flat lesions endoscopy colonoscopic resection colonoscopy data review data collection
mind body intervention for covid-19 long haul syndrome

Conditions: COVID-19 Long Haul Syndrome

Summary: the present study is a feasibility study in which we will determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associated with the covid long haul syndrome.

this study is a pilot and feasibility study to determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associated with the covid long haul syndrome in patients without evidence of ongoing tissue injury. we will perform a 12-week intervention consisting of a series of classes which will focus on knowledge therapy, desensitization, emotional expression, and stress reduction.

Eligibility criteria:
inclusion criteria: * adult patient ≥ 18 years old * new symptoms attributed to the post-covid long-haul syndrome (extremity pain, dyspnea, headaches, chest pain, fatigue) occurring after an acute phase of covid19 * minimum of at least 12 weeks after the end of the acute phase of covid-19 infection * persistence of symptoms for a least 1 month with no identified other organic etiology * score ≥ 3 or more on the sss-8 score * symptoms present for a minimum of 4 days a week * willingness to consider mind-body intervention exclusion criteria: * patients \< 18 years of age * patients \> 60 years of age * diagnosed (non-covid-19) organic disease as cause of pain, such as (but not limited) to malignancy, neurologic disorder (i.e., amyotrophic lateral sclerosis), cauda equina syndrome (note that pain related to disc disease is not an exclusion unless there are neurological impairments). * patients with previous severe covid-19 disease, defined as those who had been admitted to the icu or have objective evidence of ongoing organ injury (e.g., persistent chest radiographic abnormalities or myocarditis) * identified lung or cardiac injury in subjects with chest pain or dyspnea (e.g., chest radiograph abnormalities, cardiac ultrasound showing myocarditis or depressed ejection fraction ) * patients with a diagnosis of significant psychiatric comorbidities such as schizophrenia or dementia
safety of allogeneic bone marrow derived mesenchymal stem cells in subjects with osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of this study is to assess the safety of stemedica's mesenchymal stem cells in patients with knee osteoarthritis. the route of administration is intraarticular. safety will be evaluated by ae/sae incidence and administration tolerance. the subjects will undergo follow-up for 52 weeks. the target population is subjects with knee osteoarthritis (grade ii-iii in kellgren-lawrence scale).


Eligibility criteria:
inclusion criteria: * male or female volunteers between 35-65 years. * x-ray evidence of osteoarthritis (grade ii-iii in kellgren-lawrence). * chronic joint pain (\>5 visual analogue scale) in knee. * bmi ≤ 29. * voluntary acceptance and signature of informed consent. * willing to attend study visits and lab sample recollection. * lab values within normal reference values. * willing to use effective birth control methods. exclusion criteria: * inflammatory arthritis. * generalized infection. * active cancer or history of cancer in the past 5 years. * receiving oral or intraarticular steroids. * positive labs for hiv, hepatitis b or c. * recent trauma in the target joint. * debris in joint. * subjects that have undergone or need to undergo arthroscopic knee surgery in the target joint. * history of joint substitution, intraarticular fractures, osteotomy, arthroplasty or menisectomy. * clinically significant knee misalignment. * other illnesses that the investigator considers clinically significant. * participating in another clinical trial three months before enrolling. * women that are pregnant, lactating or result positive in the pregnancy test during screening. * known allergies to bovine products. * subjects taking anticoagulants.

Keywords: knee osteoarthritis, safety, mscs
the wrist-free study - comparing traditional above elbow casts to ones that free the wrist

Conditions: Supracondylar Humerus Fracture

Summary: this randomized controlled trial compares clinical outcomes, patient comfort and satisfaction of freeing the wrist in casts for supracondylar humerus fractures in children.


Eligibility criteria:
inclusion criteria: * type i and type iia supracondylar humerus fracture exclusion criteria: * history of elbow injury * polytrauma

Keywords: pediatric
treatment of perianal disease using adipose-derived stem cells

Conditions: Perianal Fistula; Crohn Disease

Summary: this study will compare healing and surgical outcomes in patients with chronic perianal disease treated with adipose-derived stem cells (ascs) to outcomes in patients treated in traditional surgical techniques without ascs. the study will perform retrospective medical record analysis to clinically characterize patients that have undergone these surgical procedures and compare follow-up data and disease status to determine efficacy of treatment with ascs compared to similar treatments without the use of ascs. this will help determine overall efficacy of the treatment as well as determine patient characteristics that may predict treatment success. the study will also prospectively recruit patients with perianal disease that are planning to receive treatment with ascs, and analyze their outcomes in the same way. medical record review of outcomes in patients with perianal disease that received treatment with ascs compared to those that did not will determine efficacy of this procedure.

specific aims: 1. conduct a retrospective review of health information data from patients who have undergone surgery with a colorectal surgery attending at the university of california san diego, including surgical treatment of perianal fistulas or other chronic perianal diseases, with or without injection of lipoaspirate containing adipose-derived stem cells. patient data from december 2013 to april 1, 2018, will be obtained, with parameters including date of birth, sex, date of surgery, medical history, surgical history, laboratory values, perioperative data such as blood loss, length of surgery, operative complications, readmissions, and long-term complications and status of disease. 2. conduct an observational study comparing outcomes of patients that plan to undergo treatment of perianal disease using ascs compared to those that do not use ascs. patients identified as candidates for the procedure by the colorectal surgeons and are planning to undergo the procedure will give informed consent and be recruited into the study. participants will undergo isolation of ascs using the revolve ™ system and injection of ascs into perianal wounds. clinical data will be analyzed to determine efficacy of the procedure as a means of treating perianal disease. 3. use the above data to clinically characterize patients that undergo this surgical procedure and what patient characteristics may determine outcomes. comparing follow-up data and disease status will determine efficacy of treatment with adipose-derived stem cells compared to similar treatments without the use of stem cells.

Eligibility criteria:
inclusion criteria: 1. adult men and women, age 18 years of age 2. diagnosis of perianal disease with tissue defect or chronic wound 3. underwent, or candidate for, surgery for perianal disease with colorectal surgery attending at ucsd 4. any ethnic background 5. any health status 6. minimum of 30 days postoperative follow-up exclusion criteria: 1. pregnant women 2. children less than 18 years old 3. prisoners
coverage and validity of the swedish registry of cardiopulmonary resuscitation regarding in-hospital cardiac arrest

Conditions: In-hospital Cardiac Arrest

Summary: the study will have an observational retrospective cross-sectional design. patient records and hospital administrative systems at 10 hospitals in sweden will be searched using icd-codes to find all patients treated for an in-hospital cardiac arrest (ihca) during the time period of 20180101 to 20191231. all found patients will be cross-checked against reported patients in the swedish registry of cardiopulmonary resuscitation (srcr). any differences in patient characteristics or regarding situation factors between reported and non-reported patients will be evaluated. non-reported patients will be retrospectively reported to the registry. an incidence of ihca will be calculated using the number of patients treated for ihca divided by number of hospital admissions during the specific time period. selected variables will be evaluated regarding compliance to report and regarding concordance with patient records. all missing data will be described and evaluated. local reporting procedures at each hospital will be described and evaluated regarding compliance to report and regarding missing data.


Eligibility criteria:
inclusion criteria: * all patients after the neonatal period that have been treated for an in-hospital cardiac arrest. exclusion criteria: * patients with an in-hospital cardiac arrest that is not treated (do not attempt resuscitation) or patients in the neonatal period.
deep brain stimulation for parkinson's disease: the globus pallidus internus versus subthalamic nucleus

Conditions: Parkinson Disease

Summary: this study provides an evaluation of 30 patients in 3 years, from the unified health system (sus) irrespective of region of the country, signed with clinical parkinson's disease in its intermediate stage and that the drug therapy is limited by side effects or beneficial effects provided by prior medication no longer be obtained even at high doses and have therefore the indication for treatment with deep brain stimulation.

the aim of this retrospective study is to compare motor and non-motor (olfactory, pain, cognition and metabolism) symptoms of the effects of deep brain stimulation target to the nucleus globus pallidus versus the subthalamic nucleus in patients with parkinson´s disease.

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of idiopathic parkinson's disease according to the international criteria that have not responded adequately to treatment with medication or who have complications related to prolonged use of l-dopa. * patients who may be in the anesthetized or local or general anesthesia does not incur higher than expected risk in the general population. * patients intellectually able to understand and sign the consent form. * patients with hematological, metabolic and normal coagulation. exclusion criteria: * age below 18 years * impossibility to consent to participate in the study. * patients during treatment with anti-coagulants or anti-platelet agents. * patients with anatomical abnormalities that preclude access to the implantation of electrodes (eg cranial tumors or intracranial or cysts). * patients with uncontrolled infection or other medical conditions pre-existing non-controlled (eg decompensated diabetes, hypertension, heart disease or symptomatic air). * history of primary or secondary myocardial ischemia, congestive heart failure, cardiac arrhythmia or bundle branch block refractory to treatment. * concomitant treatment with other experimental drugs. * pregnant or lactating.

Keywords: parkinson deep brain stimulation globus pallidus subthalamic nucleus
study of dehydroepiandrosterone treatment for poor responders in in vitro fertilization patients

Conditions: Infertility; Poor Responder to IVF Treatment

Summary: the aim of this study is to show solid evidences of the efficacy of dhea in improving the success rates of in-vitro fertilization (ivf) patients facing poor ovarian reserve.

poor responders to ivf treatment occurs in 5-24% of in-vitro fertilisation (ivf) cycles, resulting in the cancellation of the cycle translating in very low pregnancy rate. current interventions based upon the use of different stimulation regimen do not address the fundamental underlying physiological basis of follicular recruitment and development. the over-riding objective of this proposal is to devise novel therapeutic approaches to the treatment of poor responders of ivf treatment through dietary supplementation with dehydroepiandrosterone (dhea). the investigators hypothesise that dhea supplementation leads to improvements in ovarian steroidogenesis in poor responders, leading to improved ivf outcome. specifically, the investigators aim to 1. conduct a prospective randomised controlled trial (rct) on the effects of dhea supplementation in women who are poor responders to ivf treatment. 2. investigate the effects of dhea supplementation on ovarian steroidogenesis and biochemical and ultrasonographic markers of ovarian reserves.

Eligibility criteria:
inclusion criteria: * all women who meet one of the two following bologna criteria for poor responder: an abnormal ovarian reserve test (amh \ 10 iu/l ), or where fewer than 4 oocytes were retrieved or fewer than 4 follicles were observed in a previous ivf stimulation cycle with either standard long or antagonist protocols * where informed consent can be obtained exclusion criteria: * previous or current dhea supplementation * previous and current use of corticosteroids * major systemic illnesses * allergy to dhea
inpatient self monitoring and administration study (ismas)

Conditions: Diabetes Mellitus; Hyperglycemia; Hypoglycemia

Summary: ismas is designed to test the hypothesis that self management of insulin dependent diabetes mellitus by selected patients admitted for elective surgery is more efficacious than standard care with respect to overall glycemic control, attaining finger-stick blood sugars, and administering insulin.


Eligibility criteria:
inclusion criteria: 1. male or female, age \< 80 2. most recent hemoglobin a1c within the past 6 months \< 12% 3. recent history of regular self-administered peripheral blood glucose checks as an outpatient 4. recent history of insulin self-administration at least twice a day as an outpatient 5. admitted for a hospitalization anticipated to last at least 3 days 6. mini mental status examination (mmse) ≥ 25 at admission and the same or better post-operatively 7. all patients will be actively followed by the endocrinology inpatient consultation team during the hospitalization. exclusion criteria: 1. currently receiving peritoneal or hemodialysis 2. patients with unstable angina 3. history of myocardial infarction within 3 weeks prior to enrollment 4. current admission due to or associated with altered mental status or encephalopathy 5. history of an episode of altered mental status or encephalopathy within the 4 weeks prior to enrollment 6. a confirmed diagnosis of dementia 7. inability to self-adjust insulin 8. no recent history of ability to perform regular peripheral blood glucose checks 9. frequency of hypoglycemia (\ twice/week by history 10. inability to eat without assistance 11. study objectives will not be pursued in patients during stays in any intensive care unit.

Keywords: diabetes mellitus hyperglycemia hypoglycemia self care
multimodal model for efficacy prediction cetuximab in colorectal cancer liver metastasis patient

Conditions: Colorectal Cancer Liver Metastases

Summary: establishment and validation of the deep learning model of cetuximab efficacy in simultaneous ras wild unresectable crlm patients

ras wild unresectable crlm patients with primary tumor resection followed by cetuximab in combination with chemotherapy were included in this study. the tumor response was assessed by local mdt group. based on tumor response, almost 100 crlm patients were classified into two groups (clinician drived regimen vs multi-omics model drived regimen). they will be the prospective cohort to validate our deep learning model for predicting cetuximab efficacy.

Eligibility criteria:
inclusion criteria: 1. age 18-75 years; 2. histologically proven colorectal adenocarcinoma; 3. simultaneous liver-limited metastases; 4. initially unresectable liver metastases determined by a local mdt; 5. life expectancy of \> 6 months; 6. ras and braf v600e wild-type; 7. ecog 0-1; 8. available ct imaging before treatment. exclusion criteria: 1. previous systemic treatment for metastatic disease; 2. previous surgery for metastatic disease; 3. extrahepatic metastases; 4. unresectable primary tumor; 5. major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, cva) within 12 months before randomisation; 6. acute or subacute intestinal obstruction; 7. second primary malignancy within the past 5 years; 8. drug or alcohol abuse; 9. no legal capacity or limited legal capacity; 10. uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3 antihypertensive drugs;
study of bay1834942 in patients with solid tumors

Conditions: Advanced CEACAM6-expressing Solid Tumors

Summary: this is an open-label, phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the anti-carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (ceacam6) antibody bay1834942 in patients with advanced solid tumors known to have a prevalence for ceacam6 expression. the study consists of dose escalation and a tumor type-specific expansion.

the primary objectives of the study are to evaluate and characterize the tolerability and safety profile of repeated doses of bay1834942, and to characterize the pharmacokinetics of bay1834942 after single dose. secondary objectives are to evaluate the tumor response profile, pharmacodynamics, pharmacokinetics and immunogenicity after multiple doses of the drug.

Eligibility criteria:
inclusion criteria: * male or female patients aged ≥ 18 years * patients with histologically confirmed advanced/ metastatic solid tumors: dose escalation: solid tumor types with a expression of ceacam6 (gastric/ gej cancer, esophageal cancer, nsclc, crc, pancreatic cancer, cervical cancer, breast cancer, bladder cancer, head and neck squamous cell cancer, bile duct cancer); dose expansion: advanced adeno nsclc, crc and gastric/ gej adenocarcinoma. * ecog-ps of 0 to 1. * adequate organ function (bone marrow, liver, kidneys). * adequate coagulation function. * adequate cardiac function exclusion criteria: * patients with active symptomatic or untreated brain metastases; possible exceptions for patients with treated asymptomatic central nervous system metastases * active autoimmune disease * history or evidence of active pulmonary fibrosis, organizing pneumonia, or pneumonitis. * risk factors for bowel obstruction or bowel perforation * history of cardiac disease * uncontrolled arterial hypertension despite optimal medical management * clinically relevant findings in electrocardiogram * hiv infection * active hbv or hcv infection

Keywords: first-in-human immuno-oncology ceacam6 checkpoint inhibition